Aiforia selected by Institut Curie for AI-assisted cancer diagnostics

Aiforia Technologies Plc, Press Release, October 27, 2025 at 10:30 a.m. EET

Institut Curie in France has selected Aiforia Technologies as a partner for AI-assisted diagnostics in pathology. The collaboration involves utilizing Aiforia’s CE-IVD marked clinical AI solutions for breast and prostate cancer diagnostics. These solutions provide a comprehensive digital platform, powered by multiple AI models, that supports the entire diagnostic workflow. The agreement is signed for a one-year term.

"We are delighted to now have Aiforia’s technology in routine use for breast and prostate cancer diagnosis, thanks to funding from the ARS Ile de France. With this new acquisition, the teams at Institut Curie, leader in digital pathology, are strengthening their expertise in this field and benefiting from the most powerful AI technology available, ensuring rapid, accurate, and reliable diagnosis so that every patient receives the best possible care," says Professor Anne Vincent-Salomon, Head of Diagnostic and Theranostic Medicine at Institut Curie and Director of the Institute of Women’s Cancers.

“We are pleased to announce our partnership with the Institut Curie, supporting their journey towards integrating AI-powered diagnostics into their pathology practice. This collaboration marks another key milestone in Aiforia’s expansion across Europe, and particularly in France, where we have recently established a local subsidiary to strengthen our presence and better serve our growing customer base. The partnership reinforces our commitment to delivering innovative solutions and exceptional value to our customers,” says Jukka Tapaninen, CEO of Aiforia.

Institut Curie is France’s leading cancer center, combining a world-renowned research institute with a state-of-the-art hospital group. It treats all types of cancer, including the rarest forms. The Institut Curie Hospital Group offers a wide range of oncology treatments across its three sites in Paris, Saint-Cloud, and Orsay.

Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/

Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

About Aiforia 

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient. 

Find out more at www.aiforia.com